Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.43 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.37 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | PHGDH | O43175 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30176001 | 0.98 | LOXL2 (0.44) | LOXL2LOXIDO1MAOBNSD2 | |
| Hydrochloric Acid SCHEMBL23166308 | 0.98 | LOXL2 (0.44) | LOXL2LOXIDO1MAOBNSD2 | |
| SCHEMBL18266613 | 0.86 | LOXL2 (0.38) | LOXL2LOXIDO1MAOBNSD2 | |
| SCHEMBL15385131 | 0.84 | DAO (0.48) | LOXL2LOXIDO1MAOBNSD2 | |
| SCHEMBL10659027 | 0.83 | ESR1 (0.43) | IDO1OPRK1ALKBH5NOTUMPHGDH | |
| Hydrochloric Acid SCHEMBL23165936 | 0.82 | DAO (0.47) | LOXL2LOXIDO1MAOBNSD2 | |
| SCHEMBL10233484 | 0.82 | PDE2A (0.41) | IDO1OPRK1ALKBH5NOTUMPHGDH | |
| SCHEMBL8690013 | 0.81 | LOXL2 (0.47) | LOXL2LOXIDO1MAOBNSD2 | |
| SCHEMBL23349911 | 0.80 | OPRK1 (0.40) | IDO1OPRK1ALKBH5NOTUMPHGDH | |
| SCHEMBL122429 | 0.80 | OPRK1 (0.37) | IDO1OPRK1ALKBH5NOTUMPHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| CN-118695762-A | Preparation method of composite material, light-emitting device and electronic equipment | TCL科技集团股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20230002373-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-01-05 | — | — | US | disclosed |
| WO-2021067791-A1 | OXALAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-9834513-B2 | Benzylamine derivatives | Kalvista Pharmceuticals Limited (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20170253561-A1 | Benzylamine Derivatives | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-09-07 | — | — | US | disclosed |
| US-9670157-B2 | Benzylamine derivatives | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
| US-20160039752-A1 | BENZYLAMINE DERIVATIVES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-02-11 | — | — | US | disclosed |
| US-8901316-B2 | Process for preparing aminoadamantyl carbamate derivatives | SHIONOGI & CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8901316-B2 | Process for preparing aminoadamantyl carbamate derivatives | SHIONOGI & CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
| US-20120040942-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | RESPIRATORIUS AB (SE) | 2012-02-16 | — | — | US | disclosed |
| US-8084646-B2 | Process for production of hydroxyadamantaneamine | SHIONOGI & CO., LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-8084646-B2 | Process for production of hydroxyadamantaneamine | SHIONOGI & CO., LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20110269971-A1 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE | SHIONOGI & CO., LTD. (JP) | 2011-11-03 | — | — | US | disclosed |
| US-20110269971-A1 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE | SHIONOGI & CO., LTD. (JP) | 2011-11-03 | — | — | US | disclosed |
| US-20100105923-A1 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE | SHIONOGI & CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105923-A1 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE | SHIONOGI & CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-2088136-A1 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE | Shionogi Co., Ltd. (JP) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008063670-A1 | HETEROBICYCLIC MATRIX METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002373-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | LOXL2 978/4885LOX 1268/4885IDO1 1263/4885 |
| US-20100105923-A1 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE | HAAO, CYP4A11, CYP4F11 | LOXL2 4649/4885LOX 3296/4885IDO1 1445/4885 |
| US-20120040942-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | CHRM3, ADRB1, ADRB3 | LOXL2 2252/4885LOX 1439/4885IDO1 824/4885 |
| US-20110269971-A1 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE | HAAO, CYP4A11, CYP4F11 | LOXL2 4649/4885LOX 3296/4885IDO1 1445/4885 |
| US-20160039752-A1 | BENZYLAMINE DERIVATIVES | BDKRB1, BDKRB2, KLKB1 | LOXL2 2032/4885LOX 336/4885IDO1 1225/4885 |
| US-20170253561-A1 | Benzylamine Derivatives | BDKRB1, BDKRB2, KLKB1 | LOXL2 2032/4885LOX 336/4885IDO1 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.